NasdaqGM:TNGXBiotechs
A Look At Tango Therapeutics (TNGX) Valuation After CEO Transition And Strong Recent Share Price Returns
Tango Therapeutics (TNGX) is in focus after founding CEO and President Dr. Barbara Weber retired, with board member Dr. Malte Peters stepping in as President and CEO, while she transitions to Executive Chair.
See our latest analysis for Tango Therapeutics.
The leadership change follows a period of strong price momentum, with Tango Therapeutics posting a 45.13% 1‑month share price return and a 66.14% 3‑month share price return, while its 1‑year total shareholder return is just over 3x.
If this...